TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05710289

Intervention type: BIOLOGICAL
Intervention: Immune Responses
Description: To compare the immune responses against the original strain and circulating strain prior to and post homologous dose of WHO EUA qualified COVID-19 vaccine in adults aged 18 years and older regardless of prior history of SARS-CoV-2 infection with immunogenicity profile of single heterologous dose by GBP510 vaccine acquired from GBP510_004 study.

Intervention type: BIOLOGICAL
Intervention: Immune Responses
Description: To compare the immune responses against the original strain and circulating strain prior to and post homologous dose of WHO EUA qualified COVID-19 vaccine in adults aged 18 years and older regardless of prior history of SARS-CoV-2 infection with immunogenicity profile of single heterologous dose by GBP510 vaccine acquired from GBP510_004 study.

Intervention type: BIOLOGICAL
Intervention: Immune Responses
Description: To compare the immune responses against the original strain and circulating strain prior to and post homologous dose of WHO EUA qualified COVID-19 vaccine in adults aged 18 years and older regardless of prior history of SARS-CoV-2 infection with immunogenicity profile of single heterologous dose by GBP510 vaccine acquired from GBP510_004 study.

Intervention type: BIOLOGICAL
Intervention: Immune Responses
Description: To compare the immune responses against the original strain and circulating strain prior to and post homologous dose of WHO EUA qualified COVID-19 vaccine in adults aged 18 years and older regardless of prior history of SARS-CoV-2 infection with immunogenicity profile of single heterologous dose by GBP510 vaccine acquired from GBP510_004 study.

Intervention type: BIOLOGICAL
Intervention: Immune Responses
Description: To compare the immune responses against the original strain and circulating strain prior to and post homologous dose of WHO EUA qualified COVID-19 vaccine in adults aged 18 years and older regardless of prior history of SARS-CoV-2 infection with immunogenicity profile of single heterologous dose by GBP510 vaccine acquired from GBP510_004 study.
Study: NCT05584878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Curodont repair Self- assembling peptide P11-4
Description: The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by Curodont

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ph-chi phosphorylated - nano-chitosan
Description: The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by Ph-chi phosphorylated - nano-chitosan

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CCP-ACP  +ve control  Casein phosphopeptide amorphous calcium phosphate
Description: The labial surface of each tooth in both arches from central to the first premolar on both sides will be treated by CCP-ACP
Study: NCT05710289

Intervention type: BIOLOGICAL
Intervention: Immune Responses
Description: To compare the immune responses against the original strain and circulating strain prior to and post homologous dose of WHO EUA qualified COVID-19 vaccine in adults aged 18 years and older regardless of prior history of SARS-CoV-2 infection with immunogenicity profile of single heterologous dose by GBP510 vaccine acquired from GBP510_004 study.
Study: NCT05893914

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dry Needling and intramuscular electrical stimulation to trigger points
Description: Dry needling will be applied to trigger points in at least two of the following posterior cervical muscles; splenius capitis, splenius cervicis, semispinalis capitis/cervicis, cervical multifidi (from C2-4) and obliquus capitis inferior. Following elicitation of a local twitch response, needles will be left in place and connected to a charge generating device for intramuscular electrical stimulation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dry Needling and intramuscular electrical stimulation to trigger points
Description: Dry needling will be applied to trigger points in at least two of the following posterior cervical muscles; splenius capitis, splenius cervicis, semispinalis capitis/cervicis, cervical multifidi (from C2-4) and obliquus capitis inferior. Following elicitation of a local twitch response, needles will be left in place and connected to a charge generating device for intramuscular electrical stimulation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dry Needling and intramuscular electrical stimulation to trigger points
Description: Dry needling will be applied to trigger points in at least two of the following posterior cervical muscles; splenius capitis, splenius cervicis, semispinalis capitis/cervicis, cervical multifidi (from C2-4) and obliquus capitis inferior. Following elicitation of a local twitch response, needles will be left in place and connected to a charge generating device for intramuscular electrical stimulation.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Dry Needling and intramuscular electrical stimulation to trigger points
Description: Dry needling will be applied to trigger points in at least two of the following posterior cervical muscles; splenius capitis, splenius cervicis, semispinalis capitis/cervicis, cervical multifidi (from C2-4) and obliquus capitis inferior. Following elicitation of a local twitch response, needles will be left in place and connected to a charge generating device for intramuscular electrical stimulation.
Study: NCT04686292

Intervention type: DIAGNOSTIC_TEST
Intervention: urine flow cytometry
Description: Diagnostic test of urine flow cytometry. A urine sample will be collected according to routine procedure by a study assistant. The sample will be divided into two aliquots; half for routine urine culturing, and half for Point-of-care Urine Flow cytometry (POC-UFC) analysis (UF-5000, Sysmex, Kobe, Japan). The analysis will be performed according to manufacturer's instruction and conducted by laboratory staff. Laboratory staff will be blinded to the participants diagnosis and outcome. The results of the POC-UFC analysis will not be visible to the treating physician.
Study: NCT05396352

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: TDCS involves applying small (1-2 mA) electric currents to the scalp in order to transiently modify local neuronal electrical potentials in the brain.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: TDCS involves applying small (1-2 mA) electric currents to the scalp in order to transiently modify local neuronal electrical potentials in the brain.
Study: NCT04304261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canagliflozin
Description: 12 weeks of Canagliflozin(100mg/day) treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: 12 weeks of Sitagliptin (100mg/day) treatment
Study: NCT05837299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMC008
Description: allowing 10% dose error
Study: NCT04721964

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferric ammonium citrate and ferrous fumarate syrup (Ranbaxy Ranferon-12 Syrup, Ranbaxy Laboratories, Gurgaon, India)
Description: Daily supplementation with iron syrup for 13 weeks. The dosage will be calculated based on body weight and adjusted after 4 and 8 weeks of intervention
Study: NCT06078098

Intervention type: OTHER
Intervention: Clinical Information
Description: We will recruit AIH patients and collect important clinical information and laboratory investigation, together with biological samples.
Study: NCT04679155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eating Time Restriction
Description: early vs late time of day restriction

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Eating Time Restriction
Description: early vs late time of day restriction
Study: NCT05834868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THDB0206 Injection
Description: Drug: THDB0206 Injection Injected subcutaneously three times a day. Dose was individually adjusted.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin Lispro Injection
Description: Drug:Insulin Lispro Injection Injected subcutaneously three times a day. Dose was individually adjusted.
Study: NCT04797117

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: blood sample
Description: The blood samples for the study for each patient will be collected in the form of additional tubes.~* either 1 tube of blood of 4 ml and 2 tubes of blood of 10 ml once a day for 1 or 2 days maximum (or 48 ml maximum) during his hospitalization~* either 2 tubes of 10 ml or 20 ml maximum once during his hospitalization.
Study: NCT05013515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Surufatinib
Description: Patients receive oral Surufatinib at a dose of 300mg/d (once-daily dosing continuously, every 28-day treatment cycle), A total of 2 cycles were performed, and efficacy evaluation was performed at the end of each cycle or was determined to be required by the investigator. If disease progression or unacceptable toxicity occurred during the period, induction therapy was terminated early, and after corresponding treatment, surgical treatment was entered as early as possible.~Surufatinib treatment was interrupted 4-7 days before surgical treatment to maintain organ function; Note: Postoperative radiotherapy or chemoradiotherapy is permitted after radical surgery at the discretion of the investigator.
Study: NCT05919524

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Prostate SBRT (stereotactic body radiation therapy) with focal boost
Description: * Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions of 7.25 Gy to the entire prostate (including seminal vesicles) using VMAT~* mpMRI defined DIL was simultaneously boosted up to 50 Gy in 5 sessions to the mpMRI identified DIL.~* Additional urethra and bladder trigone sparing constrains~* Daily IGRT with cone beam CT and intrafraction gold-seeds fiducial tracking
Study: NCT06201468

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A SCAPULAR MOBILIZATION
Description: Two treatment groups will receive interventions as follows:~Group A (n = 21): will receive scapular mobilization combined with mobilization with movement (MWM) and capsular stretch for 4 weeks.~Group B (n = 21): will receive scapular proprioceptive neuromuscular facilitation combined with (MWM) and capsular stretch for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group A SCAPULAR MOBILIZATION
Description: Two treatment groups will receive interventions as follows:~Group A (n = 21): will receive scapular mobilization combined with mobilization with movement (MWM) and capsular stretch for 4 weeks.~Group B (n = 21): will receive scapular proprioceptive neuromuscular facilitation combined with (MWM) and capsular stretch for 4 weeks.
Study: NCT05938322

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet
Description: In the group of intervention is prescribed a ketogenic diet plan characterized by the following composition: carbohydrates \< 30g/day, 1.2g-1.5g protein/kg/day and lipids \> 65%.~This diet will be followed during the period of treatment with chemo-radiotherapy (5 weeks)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Diet
Description: The control group (SD) will follow the Mediterranean diet pattern based on ESPEN guidelines (carbohydrates 45-55%, protein 15-20% and lipids 30-35%).
Study: NCT04850378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalteparin
Description: Drug: Dalteparin 200 units/kg once a day for 4-7 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apixaban
Description: Drug: Apixaban 5 mg twice a day for 4-7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Drug: Apixaban 5 mg twice a day for 4-7 days.
Study: NCT06165913

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early implant placement(type II)
Description: in group 1, Tooth extraction will be performed with care to preserve alveolar bone walls. After 4-8 weeks from tooth extraction, dental implant will be placed

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early implant placement (type III)
Description: in group 2, Tooth extraction will be performed with care to preserve alveolar bone walls. After 12-16 weeks from tooth extraction, dental implant will be placed.
Study: NCT05682729

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Book Reading Intervention
Description: Children read books containing relevant stimuli.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Book Reading Intervention
Description: Children read books containing relevant stimuli.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Book Reading Intervention
Description: Children read books containing relevant stimuli.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Book Reading Intervention
Description: Children read books containing relevant stimuli.
Study: NCT05491395

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionation
Description: Hypofractionation scheme will comprise 40 Gy in 15 fractions
Study: NCT05817812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efanesoctocog alfa
Description: Recombinant coagulation factor VIII Fc-von Willebrand Factor-XTEN fusion protein (rFVIIIFc-VWF-XTEN)
Study: NCT04686682

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-8263
Description: Variable dose, orally Q2D with 28 days each cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JAB-8263
Description: RP2D dose, orally Q2D with 28 days each cycle
Study: NCT04792398

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Incobotulinumtoxin A (BTX A) Xeomin®
Description: Injections into the masseter muscles bilaterally (25 Units per muscle applied with 2 injections in each muscle)
Study: NCT04292080

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dimethyl Fumarate (TECFIDERA™)
Description: Dimethyl fumarate is a white to off-white powder that is highly soluble in water with a molecular mass of 144.13, containing 120 mg or 240 mg of dimethyl fumarate The starting dose for TECFIDERA is 120 mg twice a day orally. After 7 days, the dose should be increased to the maintenance dose of 240 mg twice a day orally. Body weight, gender, and age do not require dosage adjustment.

Intervention type: OTHER
Group type: OTHER
Intervention: No active : no treatment
Description: 30 patients will receive no specific treatment (standard of care) up to 24 months following randomization.
Study: NCT05032846

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound guided laparoscopic ovarian cystectomy
Description: Laparoscopic ovarian cystectomy to be performed under intra-operative ultrasound guidance.
Study: NCT06033677

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal radial artery cannulation
Description: Interventional application for invasive blood pressure monitoring

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Forearm radial artery cannulation
Description: Interventional application for invasive blood pressure monitoring
Study: NCT05148832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Systemic Corticosteroid
Description: 10 mg of systemic corticosteroids were prescribed weekly to patients to observe taste and smell sensation recovery.
Study: NCT06231290

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Adult full pulpotomy procedure
Description: The adult pulpotomy procedure of mature molars will be carried out with the use of magnification (dental loupes or microscope) in healthy patients. The procedure will be performed either by postgraduate or undergraduate operators.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adult full pulpotomy procedure
Description: The adult pulpotomy procedure of mature molars will be carried out with the use of magnification (dental loupes or microscope) in healthy patients. The procedure will be performed either by postgraduate or undergraduate operators.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adult full pulpotomy procedure
Description: The adult pulpotomy procedure of mature molars will be carried out with the use of magnification (dental loupes or microscope) in healthy patients. The procedure will be performed either by postgraduate or undergraduate operators.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adult full pulpotomy procedure
Description: The adult pulpotomy procedure of mature molars will be carried out with the use of magnification (dental loupes or microscope) in healthy patients. The procedure will be performed either by postgraduate or undergraduate operators.
Study: NCT05784662

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Workers Addressing Firearm Risk
Description: Educational intervention for social workers.
Study: NCT05453981

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transdiagnostic Sleep and Circadian Intervention
Description: Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates elements of evidence-based interventions, namely cognitive-behavioural therapy for insomnia, delayed sleep phase type, and interpersonal and social rhythm therapy. It targets common sleep disturbances in disorders and has improved disorder-focused symptoms and sleep and circadian functioning in patients with Severe mental illness (SMI).
Study: NCT04401553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cephalosporin
Description: First tier antibiotics, cephalosporin, will be given before anesthesia induction in the subjects with a history of allergy-like event to beta-lactam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Second tier antibiotic (Vancomycin)
Description: Second tier antibiotics, vancomycin, will be given before anesthesia induction for infection prevention in the subjects with a history of allergy-like event to beta-lactam (standard of care)
Study: NCT04930458

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nanosilver fluoride
Description: Nanosilver fluoride will be applied to the affected tooth in single application and then follow up after one and three months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride with casein phosphopeptides amorphous calcium phosphate
Description: Sodium fluoride with casein phosphopeptides amorphous calcium phosphatewill be applied to the affected tooth in single application and then follow up after one and three months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride varnish
Description: Sodium fluoride varnish will be applied to the affected tooth in single application and then follow up after one and three months
Study: NCT04724018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab Govitecan (SG)
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab vedotin-ejfv (EV)
Description: Intravenous infusion
Study: NCT05921760

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: ivosidenib taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recommended Combination Dose (RCD) of ivosidenib
Description: The RCD of ivosidenib taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recommended Combination Dose (RCD) of ivosidenib
Description: The RCD of ivosidenib taken once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab taken by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab taken by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab taken by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab taken by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab taken by intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab taken by intravenous infusion
Study: NCT05348876

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide (Nubeqa, BAY1841788)
Description: 600 mg (two 300 mg) tablets of darolutamide to be taken orally twice a day at about 12-hour intervals, equivalent to a total daily dose of 1200 mg.
Study: NCT06348537

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Olive Polyphenols
Description: Patients with fibromyalgia of Group 1 will consume Olive Polyphenols daily during 60 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients with fibromyalgia of Group 2 will consume a placebo daily during 60 days.
Study: NCT05796960

Intervention type: PROCEDURE
Intervention: Thyroidectomy with or without lymphadenectomy or multivisceral resection
Description: Lymph node dissection, as well as its surgical extension, was performed according to the surgeon's discretion. Multivisceral operations involved oesophagus, trachea and larynx.
Study: NCT04915703

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Flushing of PTBD catheter
Description: flushing of internal external PTBD catheter 3 times a day
Study: NCT05467735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Application of compression to bilateral lower extremities of patients using appropriately-sized elastic compression stockings.
Description: Patients in the Compression group would be subject to application of standardized lower extremity, thigh-high, elastic compression stockings within 24 hours of admission. Appropriate size of the stockings would be based on calf circumference, thigh circumference and leg length. The compression would be applied throughout the entire duration of hospitalization, provided the patient is able to tolerate it. Daily thorough skin checks for any cutaneous defects or lesions will be performed, and mobilization encouraged.
Study: NCT04259775

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Automated Insulin Dose Adjustment
Description: The system originally developed at Boston Children's Hospital, obtains CGM, insulin delivery, and activity data, from the cloud each day at approximately 8:00 PM using an Application Program Interface (API) calls to commercial companies (primarily Glooko and Tidepool) that aggregate data from different devices used to manage glucose levels in individuals. A detailed statistical and control analysis (see preliminary data study 1 for algorithm details) of the data are then conducted to determine if a change in therapy is required. If the analysis indicates a change in therapy is required, the patient or parent is notified by text or email directing then to a web portal detailing the change. The patient or parent can accept or modify the recommended change. If a change is made, the AIDA system confirms that the change is correctly implemented into the patient's pump or Bluetooth enabled pen when the patient next uploads the device data to the cloud.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Standard Care - change in therapy settings effected at regularly scheduled patient visits